In an opinion dated July 27, 2017, the CAFC held in Regeneron Pharmaceuticals v. Merus N.V. (2016-1346) that a patent was unenforceable based on conduct during prosecution of the patent application that resulted in the patent at suit.

Click here to read the Chinese publication.